Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants

Summary

The purpose of this trial is to study the effect of adding the omega-3 fatty acid EPA and/or Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related psychoses.

Conditions

• Schizophrenia
• Schizophreniform Disorders
• Schizoaffective Disorder
• Psychotic Disorders

Interventions

DRUG

Ethyl-eicosapentaenoic acid (EPA)

Capsules, 2 g per day for 16 weeks

DRUG

Vitamins E + C

RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks

OTHER

Etyl EPA (placebo)

Paraffin oil. Capsules, each 0.5 g.

OTHER

Vitamins E+C (placebo)

Tablets containing dicalciumphosphate

Sponsors & Collaborators

• Diakonhjemmet Hospital

  collaborator OTHER

• Stanley Medical Research Institute

  collaborator OTHER

• Laxdale Ltd

  collaborator UNKNOWN

• Scandinavian Society for Psychopharmacology

  collaborator UNKNOWN

• Shipowner Emil Stray's legacy

  collaborator UNKNOWN

• Johanne and Einar Eilertsen's research fund

  collaborator UNKNOWN

• AstraZeneca

  collaborator INDUSTRY

• Solveig and Johan P. Sommer's foundation

  collaborator UNKNOWN

• Josef and Haldis Andresen's legacy

  collaborator UNKNOWN

• University of Oslo

  collaborator OTHER

• Norwegian University of Science and Technology

  collaborator OTHER

• University Hospital, Aker

  lead OTHER

Principal Investigators

• Håvard Bentsen, MD PhD · Aker University Hospital (-2004), Diakonhjemmet Hospital (2004-)

• Odd Lingjærde, MD PhD · University Hospital, Aker

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

FACTORIAL

Eligibility

Min Age

18 Years

Max Age

40 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2001-09-30

Primary Completion

2004-04-30

Completion

2004-04-30

Countries

• Norway

Study Locations